ArticleInternational journal of surgery case reports2026
Extrarenal papillary renal cell carcinoma without a renal primary: a case report.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Primary extrarenal papillary renal cell carcinoma (pRCC) without an identifiable renal lesion is exceedingly rare, with fewer than ten cases reported in the literature. From a surgical standpoint, it poses a dual challenge: establishing an accurate diagnosis and determining the extent of resection in the absence of a renal primary lesion. Case presentation: We report the case of a 77-year-old male who was diagnosed with a solitary retroperitoneal extrarenal mass, confirmed by histopathology as a type 2 pRCC. He underwent laparoscopic resection of the mass; however, early postoperative follow-up demonstrated disease progression with pulmonary lesions. Systemic immunotherapy was initiated with nivolumab, achieving a partial response at the 3-month follow-up and stable disease at 12 months. Clinical discussion: Given the limited number of reported cases, the optimal management of extrarenal pRCC remains unclear. This case supports the potential role of immunotherapy and highlights the diagnostic and therapeutic challenges of such rare presentations. Conclusion: Extrarenal pRCC is a rare and challenging diagnostic entity. Multidisciplinary evaluation - including contrast-enhanced imaging, pathology, and surgical and medical oncology - is essential for accurate management. Immunotherapy may represent a therapeutic option in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.